drugset / Trial / NCT00661921
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to investigate the effects of blocking IL-1 signaling with AMG 108 in type 2 diabetes mellitus patients on glycemic control, as measured by change in HbA1c from baseline to end of treatment (EOT).
Timeline
- Start
- 2008-06
- Primary completion
- 2009-06
- Completion
- 2009-10
Outcome
Outcome not reported
Stopped: “Program Development discontinued”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | AMG 108 | Monoclonal antibody | 40 mg | Subcutaneous |
| Comparator | AMG 108 | Monoclonal antibody | 75 mg | Subcutaneous |
| Comparator | AMG 108 | Monoclonal antibody | 150 mg | Subcutaneous |